Third-Party Review: FDA Seeks Tangible 510(k) Results Over Next Three Years
Executive Summary
Under a new plan and draft guidance issued by US FDA, the agency is hoping to streamline and improve its third-party review program. The goal is to spend substantially less FDA resources re-reviewing low-to-moderate risk 510(k) applications that go through the program and allow products to enter market sooner.
You may also be interested in...
FDA Moves Ahead With Third-Party 510(k) Review
A new guidance document from the US FDA discusses how the agency will accredit and oversee third-party reviewers, as well as how it will determine which 510(k) devices are eligible for outside review.
Public Interest Groups Will Leverage ‘Bleeding Edge’ Lessons To Push For Device Safety Changes
Public health organizations including the Facebook group ASHES/E-Sisters, and the National Center for Health Research, are pushing for wider distribution of and a big impact from the "The Bleeding Edge" Netflix documentary. They tell Medtech Insight that they will continued to lobby Congress and US FDA to put more safety regulations and protocols into place for devices.
FDA Looks To Whittle Down Dx Review Load With Pre-Certs, Third-Party Assists
US FDA Commissioner Scott Gottlieb and the agency’s new diagnostics office chief Tim Stenzel want to use a combination of pre-certification, assistance from third-party reviewers and review exemptions to help quickly clear the tsunami of molecular-based diagnostic tests expected to be submitted to FDA for review in the next several years.